Jie Li1, Ming-Han Li1, Tian-Tian Wang1, Xiao-Ning Liu2, Xiao-Ting Zhu3, Yun-Zhang Dai1, Ke-Chao Zhai1, Yong-da Liu1, Jia-Li Lin1, Rui-Liang Ge4, Shu-Han Sun1, Fang Wang5, Ji-Hang Yuan6. 1. Department of Medical Genetics, Naval Medical University, Shanghai, China. 2. Core Facility of Basic Medical Sciences, Shanghai Jiao Tong University School of Medicine, Shanghai, China. 3. Department of Anatomy and Physiology, Shanghai Jiao Tong University School of Medicine, Shanghai, China. 4. The Second Department of Liver Surgery, Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai, China. 5. Department of Medical Genetics, Naval Medical University, Shanghai, China. wfsjz@163.com. 6. Department of Medical Genetics, Naval Medical University, Shanghai, China. jihangyuan@smmu.edu.cn.
Abstract
BACKGROUND: Many molecular alterations are shared by embryonic liver development and hepatocellular carcinoma (HCC). Identifying the common molecular events would provide a novel prognostic biomarker and therapeutic target for HCC. METHODS: Expression levels and clinical relevancies of SLC38A4 and HMGCS2 were investigated by qRT-PCR, western blot, TCGA and GEO datasets. The biological roles of SLC38A4 were investigated by functional assays. The downstream signalling pathway of SLC38A4 was investigated by qRT-PCR, western blot, immunofluorescence, luciferase reporter assay, TCGA and GEO datasets. RESULTS: SLC38A4 silencing was identified as an oncofetal molecular event. DNA hypermethylation contributed to the downregulations of Slc38a4/SLC38A4 in the foetal liver and HCC. Low expression of SLC38A4 was associated with poor prognosis of HCC patients. Functional assays demonstrated that SLC38A4 depletion promoted HCC cellular proliferation, stemness and migration, and inhibited HCC cellular apoptosis in vitro, and further repressed HCC tumorigenesis in vivo. HMGCS2 was identified as a critical downstream target of SLC38A4. SLC38A4 increased HMGCS2 expression via upregulating AXIN1 and repressing Wnt/β-catenin/MYC axis. Functional rescue assays showed that HMGCS2 overexpression reversed the oncogenic roles of SLC38A4 depletion in HCC. CONCLUSIONS: SLC38A4 downregulation was identified as a novel oncofetal event, and SLC38A4 was identified as a novel tumour suppressor in HCC.
BACKGROUND: Many molecular alterations are shared by embryonic liver development and hepatocellular carcinoma (HCC). Identifying the common molecular events would provide a novel prognostic biomarker and therapeutic target for HCC. METHODS: Expression levels and clinical relevancies of SLC38A4 and HMGCS2 were investigated by qRT-PCR, western blot, TCGA and GEO datasets. The biological roles of SLC38A4 were investigated by functional assays. The downstream signalling pathway of SLC38A4 was investigated by qRT-PCR, western blot, immunofluorescence, luciferase reporter assay, TCGA and GEO datasets. RESULTS: SLC38A4 silencing was identified as an oncofetal molecular event. DNA hypermethylation contributed to the downregulations of Slc38a4/SLC38A4 in the foetal liver and HCC. Low expression of SLC38A4 was associated with poor prognosis of HCC patients. Functional assays demonstrated that SLC38A4 depletion promoted HCC cellular proliferation, stemness and migration, and inhibited HCC cellular apoptosis in vitro, and further repressed HCC tumorigenesis in vivo. HMGCS2 was identified as a critical downstream target of SLC38A4. SLC38A4 increased HMGCS2 expression via upregulating AXIN1 and repressing Wnt/β-catenin/MYC axis. Functional rescue assays showed that HMGCS2 overexpression reversed the oncogenic roles of SLC38A4 depletion in HCC. CONCLUSIONS: SLC38A4 downregulation was identified as a novel oncofetal event, and SLC38A4 was identified as a novel tumour suppressor in HCC.
Authors: Ju-Seog Lee; Jeonghoon Heo; Louis Libbrecht; In-Sun Chu; Pal Kaposi-Novak; Diego F Calvisi; Arsen Mikaelyan; Lewis R Roberts; Anthony J Demetris; Zongtang Sun; Frederik Nevens; Tania Roskams; Snorri S Thorgeirsson Journal: Nat Med Date: 2006-03-12 Impact factor: 53.440
Authors: P Y Hernanda; K Chen; A M Das; K Sideras; W Wang; J Li; W Cao; S J A Bots; L L Kodach; R A de Man; J N M Ijzermans; H L A Janssen; A P Stubbs; D Sprengers; M J Bruno; H J Metselaar; T L M ten Hagen; J Kwekkeboom; M P Peppelenbosch; Q Pan Journal: Oncogene Date: 2014-12-22 Impact factor: 9.867
Authors: Yotaro Kudo; Masayuki Sugimoto; Esperanza Arias; Hiroaki Kasashima; Thekla Cordes; Juan F Linares; Angeles Duran; Yuki Nakanishi; Naoko Nakanishi; Antoine L'Hermitte; Alex Campos; Nadia Senni; Tarmo Rooslid; Lewis R Roberts; Ana Maria Cuervo; Christian M Metallo; Michael Karin; Maria T Diaz-Meco; Jorge Moscat Journal: Cancer Cell Date: 2020-06-25 Impact factor: 31.743
Authors: Josep M Llovet; Robin Kate Kelley; Augusto Villanueva; Amit G Singal; Eli Pikarsky; Sasan Roayaie; Riccardo Lencioni; Kazuhiko Koike; Jessica Zucman-Rossi; Richard S Finn Journal: Nat Rev Dis Primers Date: 2021-01-21 Impact factor: 52.329
Authors: R Urtasun; M Elizalde; M Azkona; M U Latasa; O García-Irigoyen; I Uriarte; M G Fernández-Barrena; S Vicent; M M Alonso; J Muntané; J Prieto; M A Ávila; C Berasain Journal: Oncogene Date: 2016-01-25 Impact factor: 9.867
Authors: Diana Becker; Ioannis Sfakianakis; Markus Krupp; Frank Staib; Aslihan Gerhold-Ay; Anja Victor; Harald Binder; Maria Blettner; Thorsten Maass; Snorri Thorgeirsson; Peter R Galle; Andreas Teufel Journal: Mol Cancer Date: 2012-08-14 Impact factor: 27.401